Table 2.
Cardiac function changes by eNOS, PPARγ, Akt and PI3K inhibitors
| MIR+Tg | MIR+Tg+L-NIO | MIR+Tg+GW9662 | MIR+Tg+LY294002 | MIR+Tg+Triciribine | |
|---|---|---|---|---|---|
| LVEDP (mmHg) | 4.7±0.5 | 7.6±0.7* | 7.2±0.4* | 6.8±0.5* | 6.9±0.4* |
| LVSP (mmHg) | 97.2±8.2 | 64.5±8.1* | 65.6±6.8* | 67.5±5.9* | 61.2±8.2* |
| (dP/dt) max (mmHg/s) | 3326.4±256.8 | 2259.4±301.2* | 2236.4±311.4* | 2351.6±259.3* | 2567.8±266.5* |
| -(dP/dt) min (mmHg/s) | 3459.4±278.6 | 2351.2±266.4* | 2410.2±268.5* | 2311.5±284.5* | 2634.5±261.4* |
| MAP (mmHg) | 68.5±5.9 | 41.6±4.9* | 39.8±6.6* | 41.5±7.2* | 40.2±5.9* |
Note: The influences of eNOS, PPARγ, Akt and PI3K inhibitors (L-NIO, GW9662, LY294002 and triciribine, respectively) on cardiac function are shown in the table. Values are expressed as the Mean ± SD.
*
p<0.05 compared to the MIR+WT.
N = 12 per group.